-
2 months ago | 
cgtlive.com | Bhagirathbhai Dholaria |Noah Stansfield
Poseida Therapeutics is currently evaluating P-BCMA-ALLO1, an allogeneic BCMA-directed chimeric antigen receptor T-cell (CAR-T) therapy, in an ongoing phase 1/1b clinical trial (NCT04960579) for the treatment of relapsed/refractory (r/r) multiple myeloma (MM).
-
2 months ago | 
cancernetwork.com | Luciano Costa |Bhagirathbhai Dholaria |Carl Ola Landgren |Muhamed Baljevic
February 11, 2025By Panelists discuss key strides made in 2024, including exciting data presented at the 66th American Society of Hematology Annual Meeting and Exposition (ASH 2024), and reflect on pivotal developments, such as new insights into Bruton tyrosine kinase inhibitors, that are shaping clinical practice while looking ahead to 2025 with anticipation for continued advancements that will further enhance treatment strategies and patient outcomes.
-
2 months ago | 
cancernetwork.com | Luciano Costa |Bhagirathbhai Dholaria |Carl Ola Landgren |Muhamed Baljevic
February 11, 2025By Panelists discuss how bispecifics, like teclistamab, are administered at their institutions, the monitoring of cytokine release syndrome (CRS) and immune effector cell–associated neurotoxicity syndrome (ICANS) during step-up dosing, and strategies to improve care transitions between academic centers and community practices.
-
2 months ago | 
cancernetwork.com | Luciano Costa |Bhagirathbhai Dholaria |Carl Ola Landgren |Muhamed Baljevic
February 11, 2025By Panelists discuss how bispecifics are sequenced with other B-cell maturation antigen (BCMA)–targeted therapies, such as chimeric antigen receptor (CAR) T cells or antibody drug conjugates (ADCs), and whether early vs late relapse impacts treatment strategies for relapsed/refractory multiple myeloma (R/R MM), with emphasis on how biological and clinical factors influence decision-making.
-
2 months ago | 
nature.com | Luciano Costa |Binod Dhakal |Bhagirathbhai Dholaria |Saurabh Chhabra
Response and progression criteria are necessary for any malignancy to standardize assessment of efficacy across trials. In multiple myeloma (MM), the International Myeloma Working Group (IMWG) established universally accepted criteria for response and progressive disease (PD) anchored on serum and urine paraprotein as primary biomarkers of disease burden [1]. The therapeutic landscape of newly diagnosed MM (NDMM) evolves rapidly.
-
Nov 21, 2024 | 
cgtlive.com | Bhagirathbhai Dholaria |Noah Stansfield
Poseida Therapeutics is currently evaluating P-BCMA-ALLO1, an allogeneic BCMA-directed chimeric antigen receptor T-cell (CAR-T) therapy, in an ongoing phase 1/1b clinical trial (NCT04960579) for the treatment of relapsed/refractory (r/r) multiple myeloma (MM). The company recently presented data from the trial at the 21st International Myeloma Society (IMS) Annual Meeting, held September 25 to 28, in Rio de Janeiro, Brazil. CGTLive® followed up with trial investigator Bhagirathbhai R.
-
Nov 17, 2024 | 
cgtlive.com | Bhagirathbhai Dholaria |Noah Stansfield
“Given the fact that this is an allogenic product, it's readily available. There is no leukapheresis needed. There is no waiting for manufacturing, which is a huge issue in autologous BCMA-targeted CAR T-cell therapy, which is takes anywhere from 4 to 6 weeks from the time of leukapheresis to actual cell infusion.
-
Jun 14, 2024 | 
nature.com | Rachel Gilmore |Bhagirathbhai Dholaria |Reena V. Jayani |Bipin N. Savani |Kendall Shultes |Dwight D. Eplin
AbstractThe age effect in severe aplastic anemia (SAA) following allogeneic hematopoietic cell transplantation (HCT) favors the use of reduced intensity conditioning (RIC) regimens in older adults. We implemented a non-myeloablative regimen consisting of fludarabine, cyclophosphamide, and rituximab (FCR) to improve HCT outcomes in SAA. Patients who underwent first HCT for SAA utilizing an FCR regimen between January 2016 and May 2022 were included.
-
Apr 21, 2024 | 
nature.com | Natalie S. Callander |Jonathan Kaufman |Jacob P. Laubach |Timothy Schmidt |Brandi N. Reeves |Binod Dhakal | +8 more
AbstractIn the MASTER study (NCT03224507), daratumumab+carfilzomib/lenalidomide/dexamethasone (D-KRd) demonstrated promising efficacy in transplant-eligible newly diagnosed multiple myeloma (NDMM). In GRIFFIN (NCT02874742), daratumumab+lenalidomide/bortezomib/dexamethasone (D-RVd) improved outcomes for transplant-eligible NDMM. Here, we present a post hoc analysis of patients with high-risk cytogenetic abnormalities (HRCAs; del[17p], t[4;14], t[14;16], t[14;20], or gain/amp[1q21]).
-
Apr 10, 2024 | 
onclive.com | Bhagirathbhai Dholaria
Bhagirathbhai Dholaria, MBBS, associate professor, medicine, Division of Hematology and Oncology, Vanderbilt University Medical Center, discusses the benefits and limitations of lisocabtagene maraleucel (liso-cel; Breyanzi) for patients with relapsed/refractory chronic lymphocytic leukemia (CLL). In the phase 1/2 TRANSCEND CLL 004 trial (NCT03331198), patients with relapsed/refractory CLL received cyclophosphamide and fludarabine–based lymphodepletion followed by a single infusion of liso-cel.
